Abintus Bio is reprogramming cells in vivo to pioneer off-the-shelf medicines. In vivo medicines involve approaches to treat disease by targeting cells within the body instead of first removing them. Abintus is using their Modular Viral Platform (MVP) to discover mechanisms to reprogram any cell type in the body to target a range of diseases. This involves identifying biologics to achieve reprogramming and methods to attain tissue specificity. Currently, Abintus has developed in vivo CAR-X products that can be used to reprogram both innate and adaptive immune effector cells to trigger a robust immune response against hematologic and solid tumors. 

<p>Abintus Bio is reprogramming cells in vivo to pioneer off-the-shelf medicines. In vivo medicines involve approaches to treat disease by targeting cells within the body instead of first removing them. Abintus is using their Modular Viral Platform (MVP) to discover mechanisms to reprogram any cell type in the body to target a range of diseases. This involves identifying biologics to achieve reprogramming and methods to attain tissue specificity. Currently, Abintus has developed in vivo CAR-X products that can be used to reprogram both innate and adaptive immune effector cells to trigger a robust immune response against hematologic and solid tumors. </p>


Abintus Bio

Insights for In Vivo Genetic Medicines PART 1: Commercial Relevance

Join us during the In Vivo Cell & Gene Engineering track at the 20th Annual PEGS Boston conference #PEGS24!  Abintus CEO, Nicholas A. Boyle, will present insights on how the Abintus team is combining next generation synthetic biology technology with clinically proven components and industry-leading manufacturing processes to mitigate development risks and deliver on the exciting promise of In Vivo genetic medicines #invivo #insitu #synbio #immunooncology 

In vivo CAR T cell advances showcased at ASGCT - BioCentury

Insights for In Vivo Genetic Medicines PART 2: Manufacturing and COGS

Off-the-shelf immunotherapy drug aims to defeat cancer - ISRAEL21c

Abintus Bio Appoints Hebrew University Researcher Lior Nissim, Ph.D., As Head of Synthetic Biology and Concurrently Enters Agreement for Next-Generation, Synthetic Biology Technology to Enable In Vivo Genetic Medicines - Business Wire

New 'armed' CAR T cells can locally activate small-molecule cancer drugs - The Science Board

Abintus Bio Appoints Hebrew University Researcher Lior Nissim, Ph.D., As Head of Synthetic Biology and Concurrently Enters Agreement for Next-Generation, Synthetic Biology Technology to Enable In Vivo Genetic Medicines

Insights for In Vivo Genetic Medicines Part 3: Safety and Tolerability

Abintus Bio, Inc.

Insights For In Vivo Genetic Medicines Part 5: Targeting 

Abintus Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference 

Insights for In Vivo Genetic Medicines Part 4: Biodistribution

Our recent presentations at biotechnology conferences provided insights from the development of prior In Vivo genetic medicines and the challenges that lay ahead for next generation products. We received positive feedback and numerous requests for additional information so, starting next week, we will post a weekly 5-part mini-series aiming to summarize these insights and provide a framework for those interested in evaluating or advancing the In Vivo field. Our focus will be on In Vivo CAR and highlight the following topics:
1)   Commercial Relevance 
2)   Manufacturing & Cost of Goods
3)   Safety & Tolerability
4)   Biodistribution
5)   Targeting
Stay tuned!  Team Abintus.

Abintus Bio

Business:

Drug notes:

About: